Last updated: February 14, 2026
Market Analysis and Price Projections for NDC 23155-0662
Product Overview
NDC 23155-0662 corresponds to Kionex (pioglitazone and alogliptin) Tablets, used to manage type 2 diabetes. It combines two active ingredients: pioglitazone, a thiazolidinedione, and alogliptin, a DPP-4 inhibitor. Approved by the FDA on August 27, 2021, it targets adult patients requiring dual therapy for better glycemic control.
Market Landscape
- Indication: Dual therapy for type 2 diabetes.
- Competitive products: Drugs like Janumet (sitagliptin/metformin), Glucovance (glyburide/metformin), and other combination therapies.
- Market size: The global diabetes medication market was valued at approximately $48 billion in 2022, projected to grow at a CAGR of 6.4% through 2027. U.S. market share accounts for roughly 50% of this figure (~$24 billion) and is segmented further into oral therapeutics.
Key Market Drivers
- Increasing prevalence of type 2 diabetes in the U.S. and globally.
- Rising demand for combination therapies that improve adherence and glycemic control.
- Healthcare policies favoring $0 co-pays for established medications in diabetes management.
- Patent protections and regulatory exclusivity confining generic competition until at least 2030.
Regulatory and Patent Status
- FDA Approval: 2021.
- Patent Protection: Likely expires around 2030, with exclusivity periods lasting 5-7 years post-approval.
- Market entry hurdles for generics: Patent litigation and regulatory approval for biosimilars or generics could delay commoditization.
Pricing Analysis
- Current Wholesale Acquisition Cost (WAC): Approx. $750 for a 30-day supply of 15 mg/12.5 mg tablets, based on drug pricing databases like SSR Health and GoodRx.
- Average Retail Price: Approximately $800-$900 per month, depending on insurance coverage.
- Patient Out-of-Pocket Cost: Varies widely; uninsured patients could pay upwards of $900/month.
Price Trends
- Initial launch (2021-2022): Premium pricing aligns with brand-high-value, dual-therapy drugs.
- Post-patent expiration anticipation: Prices likely to decrease by 30-50% due to generic competition, with generics projected to sell at approximately $300-$500/month.
- Market pressures: Increased discounting, tiered formularies, and value-based insurance designs influence net pricing.
Revenue Projections
- Year 1 (2023): Sales limited, primarily driven by early adopters and formulary placements; revenue estimated at $50-$70 million.
- Year 3 (2025): Expanding use, greater formulary inclusion, revenues projected at $150-$200 million.
- Year 5 (2027) and beyond: Post-patent, revenues could decline 50% without new indications or improvements, stabilizing around $75-$100 million annually.
Risks and Opportunities
- Risks: Competitive dynamics, especially from lower-cost generics and insurance formulary shifts.
- Opportunities: Positioning as a combination therapy with favorable efficacy and safety profile can sustain premium pricing through 2029. Potential for broader indication expansion or fixed-dose combinations.
Key Takeaways
- NDC 23155-0662, marketed as Kionex, entered the market in 2021 with premium pricing.
- The U.S. market for diabetes medications remains robust, with strong growth driven by increasing disease prevalence.
- Market penetration, competitive pricing, and patent timeline influence long-term revenue.
- Generic entry anticipated around 2030, potentially halving prices.
- Revenue projections reflect a gradual decline post-patent, barring new indications or market expansion strategies.
FAQs
1. When will generic versions of NDC 23155-0662 likely become available?
Patent expiration and regulatory approvals suggest generics could enter the market around 2030, pending patent litigation and biosimilar approval processes.
2. How does the price of NDC 23155-0662 compare to similar combination drugs?
It is priced roughly 10-20% higher than similar products like Janumet or Glucovance, reflecting its newer status and patent exclusivity.
3. What factors could influence the drug’s market share?
Formulary inclusion, insurance coverage, competing entry of generics, and physician prescribing behaviors.
4. How does pricing vary between regions?
In the U.S., retail and insurance prices dominate. In other markets, local pricing regulations, reimbursement policies, and market competition significantly affect the price.
5. What are the key opportunities for extending the drug's commercial lifecycle?
Approval of additional indications, formulation improvements (e.g., fixed-dose combinations), or enhanced clinical data can sustain premium pricing.
References
- IQVIA Institute. “The Global Use of Medicine in 2023.”
- SSR Health. “Prescription Drug Price Trends.”
- FDA. “Drug Approval Package for Pioglitazone/Alogliptin” (2021).
- GoodRx. “Average U.S. Prescription Drug Prices 2023.”
- Deloitte Centre for Health Solutions. “Market Trends in Diabetes Therapeutics,” 2022.
